DYN · Dyne Therapeutics, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-07 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $23.50 to $23.794 inclusive. The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
5,000 |
| 2026-07-07 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4572 to $23.4553 inclusive. The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
49,193 |
| 2026-07-07 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $23.46 to $23.8628 inclusive. The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
11,665 |
| 2026-07-07 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $23.46 to $23.8628 inclusive. The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
29,587 |
| 2026-07-07 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $23.46 to $23.8628 inclusive. The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
14,844 |
| 2026-07-07 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4572 to $23.4553 inclusive. The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
124,379 |
| 2026-07-07 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4572 to $23.4553 inclusive. The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
62,543 |
| 2026-07-06 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4163 to $23.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6) through (8). The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
253,039 |
| 2026-07-06 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4163 to $23.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6) through (8). The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
100,019 |
| 2026-07-06 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4163 to $23.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6) through (8). The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
127,182 |
| 2026-06-29 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.3247 inclusive. The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
40,702 |
| 2026-06-29 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.3247 inclusive. The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
51,756 |
| 2026-06-29 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.3247 inclusive. The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
102,969 |
| 2026-06-26 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.61 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6). The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
81,903 |
| 2026-06-26 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.61 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6). The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
64,411 |
| 2026-06-26 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.61 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6). The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
162,954 |
| 2026-06-25 | Lucera Erick |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.33 to $20.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Includes 110,513 unvested RSUs. |
Common Stock
|
2,362 |
| 2026-06-25 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.255 inclusive. The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
5,019 |
| 2026-06-25 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.255 inclusive. The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
6,382 |
| 2026-06-25 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.255 inclusive. The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
12,699 |
| 2026-06-24 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.13 inclusive. The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
50,530 |
| 2026-06-24 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.13 inclusive. The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
25,397 |
| 2026-06-24 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.13 inclusive. The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
19,973 |
| 2026-06-23 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2), (6) and (7). The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
39,131 |
| 2026-06-23 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2), (6) and (7). The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
77,855 |
| 2026-06-23 | Rhodes Jason P |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2), (6) and (7). The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
30,774 |
| 2026-06-23 | Kersten Dirk |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.45 to $21.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,421,886 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
71,629 |
| 2026-06-23 | Kersten Dirk |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $21.45 to $21.495, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,421,886 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
1,657 |
| 2026-06-22 | Greene Barry E |
President |
Other↑
|
No Securities Owned
|
0 |
| 2026-06-22 | Greene Barry E |
President |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option was granted on June 22, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments through June 22, 2029. |
Stock option (right to buy)
|
57,463 |
| 2026-06-22 | Kersten Dirk |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.13 to $20.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,421,886 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
190,676 |
| 2026-06-18 | Kersten Dirk |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,685,848 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
46,901 |
| 2026-06-17 | Kersten Dirk |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,685,848 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. (Continued from Footnote 2) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
37,454 |
| 2026-06-16 | Kerr Douglas |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Includes 145,313 unvested RSUs. |
Common Stock
|
887 |
| 2026-06-16 | Cox John |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Includes 259,564 unvested RSUs. |
Common Stock
|
2,683 |
| 2026-06-16 | Friedl-Naderer Johanna |
EVP & Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.01 to $18.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Includes 123,678 unvested RSUs. |
Common Stock
|
145 |
| 2026-06-08 | Posner Brian S |
Director |
Buy↑
|
Common Stock
|
2,000 |
| 2026-06-05 | Incerti Carlo |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. |
Stock option (right to buy)
|
35,152 |
| 2026-06-05 | HURWITZ EDWARD |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. |
Stock option (right to buy)
|
35,152 |
| 2026-06-05 | Kersten Dirk |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. |
Stock option (right to buy)
|
35,152 |
| 2026-06-05 | Rhodes Jason P |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
Stock option (right to buy)
|
35,152 |
| 2026-06-05 | Posner Brian S |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. |
Stock option (right to buy)
|
35,152 |
| 2026-06-05 | Stehman-Breen Catherine |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. |
Stock option (right to buy)
|
35,152 |
| 2026-06-05 | Lubner David Charles |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. |
Stock option (right to buy)
|
35,152 |
| 2026-06-03 | Posner Brian S |
Director |
Buy↑
|
Common Stock
|
2,500 |
| 2026-05-26 | Posner Brian S |
Director |
Buy↑
|
Common Stock
|
2,000 |
| 2026-05-20 | Posner Brian S |
Director |
Buy↑
|
Common Stock
|
2,500 |
| 2026-05-13 | Friedl-Naderer Johanna |
EVP & Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.20 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Includes 126,040 unvested RSUs. |
Common Stock
|
228 |
| 2026-05-13 | Lucera Erick |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.20 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Includes 110,513 unvested RSUs. |
Common Stock
|
1,448 |
| 2026-05-13 | Kerr Douglas |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.20 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Includes 148,313 unvested RSUs. |
Common Stock
|
1,564 |